In 2019, Kingsley Leung, chairman of traditional pharmaceutical R&D company Uni-Bio Science Group, spotted an opportunity to use AI and robotics to dramatically improve the drug development process. As a result, he spun off a new company, Great Bay Bio, which makes developing new medicines faster and more efficient, potentially reducing both the time it takes and the risks of the process by half.